Janke Toni Maria, Eisner Elisabeth, Augustin Matthias, Blome Christine
Competence Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20246, Hamburg, Germany.
Allergy Asthma Clin Immunol. 2022 Oct 25;18(1):95. doi: 10.1186/s13223-022-00733-8.
Allergic rhinitis (AR) is frequent in children and adolescents and can severely affect their lives. This article describes the development and validation of a questionnaire to assess treatment needs and benefits in children and adolescents, the PBI-AR-K, in a sample of patients receiving grass pollen sublingual immunotherapy.
The PBI-AR-K was developed based on an open survey including children and adolescents and expert consensus between methodologists, patients, and physicians. The PBI-AR-K assesses patient needs before the treatment and perceived benefit during or at the end of a treatment. A weighted benefit score can be calculated ranging from 0 to 4 (4 = highest possible benefit). The validation was conducted in children (5-12 years) and adolescents (13-17 years) receiving sublingual immunotherapy. Subscales were developed based on factor analysis. Psychometric properties of items and scales were assessed with descriptive statistics, internal consistency, and convergent validity.
The final PBI-AR-K consists of 19 items. For validation, data from 345 patients (mean age 11.1; 60.9% male; n = 223 children; n = 122 adolescents) was analysed. Factor analyses resulted in four subscales for children and three subscales for adolescents. The items with the highest importance ratings were about choice of leisure activities (mean value in children: 3.5) and about being free of AR symptoms (adolescents: 3.3). The weighted PBI-AR-K scores reflected considerable patient-reported benefit (2.08-2.82) in both children and adolescents. Internal consistency of all scales was good or acceptable. In the children's sample, the global scale and three of four subscales were quite consistently correlated with convergent variables, while the subscale 'treatment burden' was significantly correlated only with change in average impairments due to rhinitis symptoms. The adolescents' sample showed more inconsistent results with only change in rhinitis severity being significantly associate with all subscales.
The newly developed PBI-AR-K is a reliable and valid questionnaire for use in children; for the use in adolescents, it should be further elaborated.
变应性鼻炎(AR)在儿童和青少年中很常见,会严重影响他们的生活。本文描述了一种用于评估儿童和青少年治疗需求及获益情况的问卷——儿童变应性鼻炎患者受益指数问卷(PBI - AR - K)的开发及验证过程,该过程基于接受草花粉舌下免疫治疗的患者样本。
PBI - AR - K是基于一项包括儿童和青少年的开放式调查以及方法学家、患者和医生之间的专家共识而开发的。PBI - AR - K评估治疗前患者的需求以及治疗期间或结束时的感知获益。可以计算出一个加权获益分数,范围从0到4(4 = 可能的最高获益)。验证工作在接受舌下免疫治疗的儿童(5 - 12岁)和青少年(13 - 17岁)中进行。基于因子分析开发了分量表。使用描述性统计、内部一致性和收敛效度评估项目和量表的心理测量特性。
最终的PBI - AR - K由19个项目组成。为进行验证,分析了345名患者的数据(平均年龄11.1岁;60.9%为男性;n = 223名儿童;n = 122名青少年)。因子分析得出儿童的四个分量表和青少年的三个分量表。重要性评分最高的项目是关于休闲活动的选择(儿童中的均值:3.5)以及无AR症状(青少年:3.3)。加权的PBI - AR - K分数反映出儿童和青少年患者报告的获益都相当可观(2.08 - 2.82)。所有量表的内部一致性良好或可接受。在儿童样本中,总体量表和四个分量表中的三个与收敛变量有相当一致的相关性,而“治疗负担”分量表仅与鼻炎症状导致的平均损伤变化显著相关。青少年样本的结果更不一致,只有鼻炎严重程度的变化与所有分量表显著相关。
新开发的PBI - AR - K是一种用于儿童的可靠且有效的问卷;对于青少年使用,还应进一步完善。